Welcome to our dedicated page for Neogenomics news (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics stock.
NeoGenomics Inc (NEO) provides cutting-edge cancer diagnostic testing and clinical consultation services to healthcare providers worldwide. This news hub delivers timely updates on the company’s advancements in molecular oncology, regulatory milestones, and strategic partnerships shaping precision medicine.
Access authoritative coverage of NEO’s latest developments, including new test launches, laboratory accreditations, and peer-reviewed research insights. Investors and clinicians will find curated updates on earnings reports, biomarker discovery initiatives, and collaborations with leading cancer centers.
Key content areas include regulatory filings, technology partnerships, clinical study outcomes, and executive leadership updates. All news is vetted for accuracy and relevance to oncology professionals and stakeholders in precision diagnostics.
Bookmark this page for streamlined access to NeoGenomics’ evolving role in cancer care innovation. Check regularly for objective reporting on developments impacting diagnostic standards and patient outcomes across global healthcare systems.
NeoGenomics (NEO) reported its Q4 and full-year 2024 results, marking its ninth consecutive quarter of double-digit revenue growth. Full-year consolidated revenue increased 12% to $661 million, while Q4 revenue grew 11% to $172 million.
The company's full-year net loss decreased 11% to $79 million, while Q4 net loss increased 7% to $15 million. Full-year adjusted EBITDA showed significant improvement, increasing 1,036% to $40 million. Average revenue per clinical test increased by 5% to $465, driven by higher value tests and strategic reimbursement initiatives.
For 2025, NeoGenomics reaffirmed its guidance, projecting revenue between $735-745 million (11-13% growth) and adjusted EBITDA of $55-58 million (38-45% growth).
NeoGenomics (NASDAQ: NEO) announced it will release its fourth quarter and full year 2024 financial results before U.S. markets open on Tuesday, February 18, 2025. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results and recent highlights.
Investors can access the live webcast through the company's Investor Relations website at ir.neogenomics.com. For those joining by phone, the dial-in numbers are (888) 506-0062 (domestic) and (973) 528-0011 (international), with participant access code 167039. A replay of the webcast will be available shortly after the call.
NeoGenomics (NASDAQ:NEO) has announced its financial guidance for 2025 and updated its Long-Range Financial Plan. The company expects total revenues of $735-745 million and adjusted EBITDA of $55-58 million for 2025, representing year-over-year growth of 11-13% and 43-51% respectively from 2024 midpoint guidance.
The company's Long-Range Plan targets include annual revenue growth of 12-13% with NGS growth of ~25% per year, gross margin expansion of 100-150 basis points annually, and adjusted EBITDA improvement of 250-300 basis points per year. NeoGenomics aims to achieve positive cash flow from operations in 2025 and serve more than 1 million patients annually by 2028.
The company plans to retire its 2025 convertible notes maturing on May 1, 2025, using cash on hand.
NeoGenomics (NASDAQ:NEO) announced that CEO Chris Smith will retire effective April 1, 2025, with board member Tony Zook named as his successor. Under Smith's leadership since August 2022, the company achieved eight consecutive quarters of double-digit revenue growth and improved from negative $48 million Adjusted EBITDA in 2022 to an expected positive $37-40 million in 2024.
The company reaffirmed its 2024 financial guidance, projecting consolidated revenue between $655-667 million, net loss of $(81)-$(78) million, and Adjusted EBITDA of $37-40 million. During Smith's tenure, NeoGenomics served more than 1.5 million cancer patients and implemented a patient and customer-centric strategy.
Incoming CEO Tony Zook brings extensive healthcare experience, including his role as Executive Vice President of Global Commercial Operations at AstraZeneca, where he managed over $30 billion in revenues. Smith will remain as an advisor during the transition period.
NeoGenomics (NASDAQ: NEO), a leading oncology testing services company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Chris Smith will deliver a presentation with a Q&A session on Wednesday, January 15, at 1:30 p.m. PT/4:30 p.m. ET. The event will be accessible through a live webcast, with a replay available on the company's Investor Relations website at ir.neogenomics.com.
NeoGenomics (NASDAQ: NEO) published a study in ESMO Open demonstrating the effectiveness of circulating tumor DNA (ctDNA) in monitoring molecular residual disease (MRD) for high-risk melanoma patients. The research, conducted with Princess Margaret Hospital, analyzed 276 plasma samples from 66 melanoma patients using NeoGenomics' RaDaR® sequencing assay.
The study revealed that ctDNA detection post-surgery can identify patients with worse prognosis and enable earlier detection of disease recurrence. Notably, the research successfully identified ctDNA in patients lacking BRAF and NRAS mutations, suggesting broader applicability compared to earlier studies. The findings have led to the development of the CLEAR-Me trial for detecting and clearing MRD in high-risk melanoma patients.
NeoGenomics (NASDAQ: NEO) will present significant research on hematologic malignancies at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego, December 7-10. The company will showcase findings on CNS lymphoma, myeloid malignancies, and gene fusions in acute myeloid leukemia.
The presentation includes a poster on neuronal-glial and immune microenvironment signatures in primary CNS lymphoma, scheduled for December 9. Additionally, two abstracts were published in the Blood supplement: one comparing genetic insights into myeloid malignancies across NCCN Guidelines, WHO Classification, and ICC System, and another studying gene fusion prevalence in 2,958 AML patients using FISH and NGS testing.
The company will also feature its hematological oncology solutions, including COMPASS, AML Express, and AML MRD Flow Panel at booth #2347.
ConcertAI and NeoGenomics (NASDAQ: NEO) have announced a joint software-as-a-service solution called CTO-H for hematological malignancies research. The solution provides the largest reference dataset ever created for hematological malignancies, featuring data from over 370,000 patient lives with 7-11 years of surveillance and comprehensive biomarker information.
The collaboration aims to address challenges in clinical trial design and execution in hematology research. CTO-H will be deployed as a SaaS solution within ConcertAI's CARAai™ cloud, with NeoGenomics providing specialized biomarker testing interpretation services. The solution will be available for pre-release evaluation immediately, with general availability scheduled for January 17, 2025.
NeoGenomics (NASDAQ: NEO) will present four abstracts at the AMP 2024 Annual Meeting & Expo in Vancouver, showcasing advancements in cancer diagnostics through ctDNA and next-generation sequencing (NGS). The presentations include research on: the G4 sequencing platform for gene fusion detection, TSO500 ctDNA v2 assay performance, enhanced workflow for Neo Comprehensive™ tumor profiling, and HPV subtyping using whole transcriptome sequencing.
The company will also host a workshop on November 20 focusing on comprehensive genomic profiling for myeloid neoplasms. These presentations demonstrate NeoGenomics' commitment to improving cancer care through precision medicine and advanced testing methodologies.
NeoGenomics (NASDAQ: NEO) has appointed Felicia Williams to its Board of Directors, effective November 1, 2024. Williams, former interim CFO of Macy's and Fellow for CEO Action for Racial Equality, brings over 35 years of experience in finance, accounting, audit, and enterprise risk management from multinational corporations including Macy's, The Coca-Cola Company, and Bristol Myers-Squibb. She will serve on the Audit and Finance and Nominating and Corporate Governance Committees. Williams currently serves on the Board of Directors of Paycom and Anywhere Real Estate.
FAQ
What is the current stock price of Neogenomics (NEO)?
What is the market cap of Neogenomics (NEO)?
